There are currently 478 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346
Recruiting
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/10/2024
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Register for Updates
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493
Recruiting
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Sarah Cannon Research Institute SCRI, Kansas City, Missouri
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
Recruiting
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: GSK Investigational Site, Kansas City, Missouri
Conditions: Multiple Myeloma
Register for Updates
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
NCT06144840
Recruiting
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
05/10/2024
Locations: Kansas City Research Institute, Kansas City, Missouri
Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Register for Updates
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/10/2024
Locations: Local Institution - 198, Kansas City, Missouri
Conditions: Crohn Disease
Register for Updates
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT03598257
Recruiting
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: University of Kansas Cancer Center - North, Kansas City, Missouri
Conditions: Breast Inflammatory Carcinoma
Register for Updates
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
NCT05705349
Recruiting
This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL [MK-8591A]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: KC CARE Health Center-Clinical Trials ( Site 5670), Kansas City, Missouri
Conditions: HIV-1 Infection
Register for Updates
STOP-T1D Low-Dose (ATG)
NCT04291703
Recruiting
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Gender:
All
Ages:
Between 6 years and 34 years
Trial Updated:
05/09/2024
Locations: The Children's Mercy Hospital, Kansas City, Missouri
Conditions: Diabetes Mellitus, Type 1
Register for Updates
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
All
Ages:
All
Trial Updated:
05/09/2024
Locations: Children's Mercy Hospital and Clinics, Kansas City, Missouri
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Register for Updates
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224
Recruiting
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Truman Medical Centers, Kansas City, Missouri +1 locations
Conditions: Metastatic Bladder Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Refractory Renal Pelvis Urothelial Carcinoma, Refractory Ureter Urothelial Carcinoma, Refractory Urethral Urothelial Carcinoma
Register for Updates